ACS Applied Nano Materials · 2021 · 19 citations · 45 references
PharmacyPharmaceuticsPharmacologyDrug DeliveryNanomaterialsNanotechnologyAdhesion MoleculesCell-nanoparticle InteractionsNanomedicineNanoparticle CharacterizationNanoparticle DesignVascular PermeabilityAtherosclerosis Molecular MechanismsBiomolecule-nanoparticle InteractionsEndothelial Adhesion MoleculesInflammatory Responses To NanoparticlesNanoparticle AdhesionNanoparticle InteractionsNanoparticle-biomolecule InteractionsVascular Cell Adhesion Molecule 1
Cardiovascular disease remains the number one cause of mortality and morbidity worldwide and includes atherosclerosis, which presents as a deadly and chronic inflammatory disease. The initial pathological factor in atherosclerosis is a dysfunctional endothelium (Dys-En), which results in enhanced permeability of the endothelium and enhanced expression of adhesion molecules such as vascular cell adhesion molecule 1 (VCAM-1), among others. Nanomedicines represent a growing arsenal of novel therapeutics aimed at treating atherosclerosis; however, nanoparticle (NP) interactions as a function of their biophysiochemical properties with the Dys-En are not currently well understood. In this study, we investigated targeted NP biophysicochemical properties for maximal VCAM-1 binding and permeability across several Dys-En models that we established using cardiovascular inflammatory mediators. We found that NP size governs permeability and binding, regardless of the type and density of VCAM-1 peptide ligand used. Our results suggest that the design of NPs in the range of 30–60 nm can highly increase permeability and binding across the Dys-En. These findings confirm the importance of in vitro models of Dys-En as a preliminary screening and predictive tool for atherosclerosis NP targeting.
45
Size‐Dependent Endocytosis of Nanoparticles
Sulin Zhang, Ju Li, George Lykotrafitis et al. · Advanced Materials · 2008 · 1.1K citations · Full text
Pharmacy, Biophysics, Pharmaceutics +17